- Home
- NSPR vs ZNTL Comparison
NSPR vs ZNTL Comparison
Compare NSPR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- ZNTL
- Stock Information
- Founded
- NSPR 2005
- ZNTL 2014
- Country
- NSPR United States
- ZNTL United States
- Employees
- NSPR N/A
- ZNTL N/A
- Industry
- NSPR Medical/Dental Instruments
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- ZNTL Health Care
- Exchange
- NSPR Nasdaq
- ZNTL Nasdaq
- Market Cap
- NSPR 99.7M
- ZNTL 118.3M
- IPO Year
- NSPR N/A
- ZNTL 2020
- Fundamental
- Price
- NSPR $1.81
- ZNTL $1.28
- Analyst Decision
- NSPR Strong Buy
- ZNTL Buy
- Analyst Count
- NSPR 2
- ZNTL 6
- Target Price
- NSPR $4.50
- ZNTL $6.53
- AVG Volume (30 Days)
- NSPR 119.5K
- ZNTL 783.4K
- Earning Date
- NSPR 11-04-2025
- ZNTL 11-06-2025
- Dividend Yield
- NSPR N/A
- ZNTL N/A
- EPS Growth
- NSPR N/A
- ZNTL N/A
- EPS
- NSPR N/A
- ZNTL N/A
- Revenue
- NSPR $7,779,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- NSPR $7.48
- ZNTL N/A
- Revenue Next Year
- NSPR $104.39
- ZNTL N/A
- P/E Ratio
- NSPR N/A
- ZNTL N/A
- Revenue Growth
- NSPR 14.04
- ZNTL N/A
- 52 Week Low
- NSPR $1.77
- ZNTL $1.01
- 52 Week High
- NSPR $3.80
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- NSPR 22.72
- ZNTL 33.22
- Support Level
- NSPR $2.05
- ZNTL $1.49
- Resistance Level
- NSPR $2.40
- ZNTL $1.54
- Average True Range (ATR)
- NSPR 0.15
- ZNTL 0.10
- MACD
- NSPR -0.03
- ZNTL -0.04
- Stochastic Oscillator
- NSPR 29.05
- ZNTL 11.24
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.